# Levicept

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/levicept

- Industry: Biotechnology
- Headquarters: Sandwich, UK
- Website: www.levicept.com
- Total disclosed funding: $16M
- Latest round: Series A (Oct 8, 2014)
- Investors on record: 3

## About

Levicept is a biotechnology firm focused on innovative therapies for chronic pain management, particularly targeting osteoarthritis with its flagship product LEVI-04, which aims to improve patient outcomes in pain relief.Levicept, founded in 2012, is based in Sandwich, UK, and specializes in the development of therapeutic solutions for chronic pain management. The company successfully raised GBP 10 million in a Series A funding round in October 2014, with investors including Gilde Healthcare and Advent Life Sciences. The firm has completed two deals to date, with LEVI-04 having successfully undertaken a phase II clinical trial, demonstrating its efficacy in treating chronic knee pain. The CEO, Eliot Forster, along with co-founder Simon Westbrook, have significant experience in the biotechnology sector.Levicept is a biotechnology company dedicated to providing innovative solutions for chronic pain management, specifically targeting osteoarthritis. Their flagship product, LEVI-04, is a biological therapy that modulates the neurotrophin pathway through neurotrophin-3, aimed at delivering effective analgesia while minimizing side effects commonly associated with traditional pain medications such as opiates and NSAIDs. The product has successfully completed a phase II clinical trial demonstrating its efficacy in treating chronic knee pain, addressing a significant unmet need for over 1 billion individuals suffering from chronic pain globally. Levicept’s primary customers include healthcare providers and institutions that seek effective pain management options for their patients. The company is focusing on expanding its reach in key geographical markets across Europe and North America, where there is a rising demand for safe and well-tolerated analgesics.Levicept’s revenue model is structured around partnerships with healthcare providers and institutions, as well as potential collaborations with pharmaceutical companies. The firm is expected to generate revenue through the distribution of LEVI-04, which will involve B2B transactions aimed at hospitals, clinics, and specialty pain management centers. Pricing structures may include tiered pricing based on volume purchases or agreements based on patient outcomes. As the product progresses through further clinical stages and potential commercialization, revenue will be derived from the direct sale of LEVI-04, as well as potential licensing agreements with larger pharmaceutical entities focused on expanding their pain management portfolios.Levicept plans to utilize the GBP 10 million raised in the Series A round in October 2014 to advance the development of LEVI-04 and explore additional product lines targeting chronic pain. The company aims to expand into key markets in Europe and North America by 2025, responding to the growing demand for effective pain management solutions. Furthermore, ongoing research and development efforts will focus on enhancing existing therapies and exploring new innovative approaches to pain management.

## Funding rounds

- Series A, Oct 8, 2014, $16M — Index Ventures, Gilde Healthcare, Advent Life Sciences
- Seed, Mar 1, 2012 — Index Ventures

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Seed, Series A
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A